Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M

HERZLIYA, Israel and CALGARY, AB, Nov. 27, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its financial consolidated results for the nine months ended September 30, 2025 and provide a Company update.

Iris Bincovich, CEO of Innocan, said: "As published in the esteemed Journal of Precision Nanomedicine and Frontiers in Pharmacology journal, Innocan continues to advance the pre-clinical development of LPT-CBD to support compliance with both the FDA and the CVM requirements for development.

Preliminary pharmacokinetic and safety evaluations of LPT-CBD in minipigs, provide encouraging support for Innocan's regulatory strategy to advance LPT-CBD IND-enabling studies in alignment with FDA standards. 

In addition, meaningful pre-clinical data provides clinically translatable insights supporting the intended chronic use of LPT-CBD for pain management.

Despite an unstable US market, the Consumer Wellness business continued to demonstrate resilience and solid profitability, together with continued strengthening of the Company's balance sheet.

We are progressing towards the next important milestone of a U.S. public offering.

FISCAL 2025 NINE MONTHS SELECT FINANCIAL RESULTS (unaudited)

• Revenues totaled US $21.6 million, representing a decrease of 10% on a reported basis for the nine months ended September 30, 2025.
• Gross Profit totaled US $19.5 million representing a decrease of 10.5% on a reported basis for the nine months ended September 30, 2025.
• Gross Margin remained high at 90.2% despite the decline in revenues in nine months ended September 30, 2025.
• Operating loss remained stable totaled US $0.333 million, representing an increase of 1.5% on a reported basis for the nine months ended September 30, 2025.

"The Company continues to deliver strong gross margins, reflecting the strength of our business model and operational execution. B.I. Sky Global has maintained its leading position across all categories and preserved its market share on Amazon, despite challenging conditions in the United States," said Roni Kamhi, CEO of B.I. Sky Global and COO of Innocan Pharma. "We developed and implemented a strategic response to tariffs and optimized our supply chain, resulting in substantial cost savings and improved gross profit performance. This positions the Company well for outperformance as the market recovers."

The Company will hold an earnings call & Investor update on Thursday November 27, 2025, at 1:00 pm EST at the following link:https://us06web.zoom.us/j/89775829140?pwd=LavOpbrncp0TPHe77KAYRRoKiXQ0Xb.1

Meeting ID: 897 7582 9140. Passcode: 783106
One tap mobile
+13017158592,,89775829140#,,,,*783106# US (Washington DC)
+13052241968,,89775829140#,,,,*783106# US

The Company's full set of unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.innocanpharma.com and its SEDAR+ profile at www.sedarplus.ca.

About Innocan

Innocan is a pharmaceutical company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients' quality of life. This segment includes its primary drug delivery technology, LPT-CBD loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: pain management and epilepsy. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan is a 60% shareholder in the joint venture company, BI Sky Global Ltd., which company focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/innocan-pharma-reports-financial-results-for-q3-2025--with-revenues-at-us-21-6m-302627377.html

SOURCE Innocan Pharma Corporation